Core Viewpoint - The approval of the injectable Cefoperazone Sodium and Sulbactam Sodium by the National Medical Products Administration of China enhances the company's position in the anti-infection sector and is expected to generate greater returns for the company and its shareholders [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Zhuhai United Pharmaceutical Co., Ltd., has received approval for the injectable Cefoperazone Sodium and Sulbactam Sodium (specification: 2.0g) [1] - This product has passed the consistency evaluation for generic drug quality and efficacy [1] Group 2: Product Characteristics - Injectable Cefoperazone Sodium and Sulbactam Sodium is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity [1] - It can be used alone or in combination for treating infections caused by sensitive bacteria, including respiratory, urinary, intra-abdominal infections, sepsis, meningitis, skin and soft tissue infections, bone and joint infections, and reproductive tract infections [1] Group 3: Market Position and Future Plans - The product is listed as a Class B drug in the National Medical Insurance Directory (2024 edition) [1] - The approval is expected to help the company strengthen its competitive advantage in the anti-infection field [1] - The company will continue to focus on new product development and advancing consistency evaluations to create greater value for the company and its shareholders [1]

本公告乃由聯邦制藥國際控股有限公司（「本公司」）自願發出。 本公司董事會（「董事會」）欣然公佈，本公司全資附屬公司珠海聯邦制藥股份有限公 司中山分公司申報的注射用頭孢哌酮鈉舒巴坦鈉（規格：2.0g）經中國國家藥品監督 管理局審批，通過仿製藥質量和療效一致性評價（「一致性評價」）。 注射用頭孢哌酮鈉舒巴坦鈉是第三代頭孢菌素類抗生素，具有廣譜抗菌活性，可單獨 或聯合用藥。單獨用藥時，適用於治療由敏感菌引起的呼吸道感染、泌尿道感染、腹 腔內感染、敗血症、腦膜炎、皮膚和軟組織感染、骨骼和關節感染、生殖道感染。其 對敏感細菌引起的系列炎症和感染均有顯著治療效果，可有效控制炎症。現時，注射 用頭孢哌酮鈉舒巴坦鈉為國家醫保目錄（二零二四年版）乙類藥品。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 ( 於開曼群島成立之有限公司 ...

Group 1 - The stock of United Pharmaceutical (03933.HK) rose over 4% in the morning session, reaching an increase of 4.08% at a price of HKD 59.95 [1] - The trading volume amounted to HKD 31.2821 million [1]

Core Viewpoint - Federal Pharmaceutical (03933) has made significant advancements in the GLP-1 treatment area, showcasing its new diabetes management products and forming strategic partnerships to enhance its global market presence [1] Group 1: Stock Performance - Federal Pharmaceutical's stock rose over 4%, reaching HKD 59.95 with a trading volume of HKD 31.28 million [1] Group 2: Product Development - The company highlighted its diabetes management product lineup at the conference, including the recently launched liraglutide injection "Federal Yuli Tai" and the upcoming semaglutide injection "Federal Youmei Tai," expected to launch next year [1] - The introduction of these products marks a significant milestone for Federal Pharmaceutical in the GLP-1 target treatment field [1] Group 3: Strategic Partnerships - Federal Pharmaceutical's subsidiary, Federal Bio, has entered into an exclusive licensing agreement with Novo Nordisk for UBT251, which underscores the global market potential of UBT251 [1] - This collaboration is expected to leverage Novo Nordisk's resources to accelerate the global development of UBT251 [1] - The partnership represents a key achievement in Federal Pharmaceutical's innovation transformation, aligning its GLP-1 innovative drugs with international standards and enhancing the international influence of domestic GLP-1 medications across nearly 80 countries and regions [1]

Core Viewpoint - Federal Pharmaceutical (03933) has shown significant stock performance, rising over 4% following the successful presentation of its diabetes treatment products at a recent conference, indicating strong market interest and potential growth in the GLP-1 treatment sector [1] Group 1: Product Development - The company showcased its diabetes product lineup, including the recently launched liraglutide injection "Federal Yuli Tai" and the upcoming semaglutide injection "Federal Youmei Tai," marking important advancements in the GLP-1 target treatment area [1] - The collaboration between Federal Pharmaceutical's subsidiary, Federal Bio, and Novo Nordisk for the exclusive licensing of UBT251 highlights the global market potential of this product and aims to accelerate its development process [1] Group 2: Strategic Partnerships - The partnership with Novo Nordisk not only validates the global market value of UBT251 but also leverages Novo Nordisk's resources to enhance the product's development [1] - This collaboration represents a significant achievement in Federal Pharmaceutical's innovation transformation, aligning its GLP-1 innovative drugs with international standards and expanding its reach to nearly 80 countries and regions [1]

Group 1 - The core viewpoint is that the Hong Kong innovative drug concept stocks are experiencing a continuous decline, with Federal Pharmaceutical dropping over 8% [1] - Other companies such as Crystal Technology Holdings, Giant Biologics, Sanofi Pharmaceutical, and China Biopharmaceutical are also following the downward trend [1]

Core Points - The company, 联邦制药 (03933), announced the issuance of 3.3698 million shares as part of its 2023 share award plan, contingent upon the achievement of performance targets for 2024 [1] Group 1 - The total number of shares awarded is 3.3698 million [1] - The shares will be allocated to relevant recipients on November 13, 2025 [1] - The allocation is based on the terms of the 2023 share award plan [1]

Core Viewpoint - The company, 联邦制药, announced the issuance of 3.3698 million shares as part of its 2023 share award plan, contingent upon the achievement of performance targets for 2024, with the shares set to vest on November 13, 2025 [1] Summary by Category - **Share Issuance**: A total of 3.3698 million shares will be awarded under the 2023 share award plan [1] - **Performance Conditions**: The vesting of these shares is dependent on the achievement of specific performance targets for the year 2024 [1] - **Vesting Date**: The shares are scheduled to vest on November 13, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 The United Laboratories International Holdings Limited 聯邦制藥國際控股有限公司 ( 於開曼群島成立之有限公司 ) (股份代號: 3933) 於本公告日期，董事會成員包括：執行董事蔡海山先生、梁永康先生、蔡紹哲女士、方 煜平先生、鄒鮮紅女士及朱蘇燕女士；以及獨立非執行董事張品文先生、宋敏教授及傅 秋實博士。 自願公告 獎勵股份的歸屬 本公告乃由聯邦制藥國際控股有限公司（「本公司」）自願發出。 茲提述本公司日期為二零二三年十一月十三日的公告（「該公告」），內容有關根據二零 二三年股份獎勵計劃的條款向承授人授出合共12,096,900股獎勵股份。除文義另有界定外， 本公告所用詞彙與該公告所賦予者具有相同涵義。 董事會公佈，共3,369,800股獎勵股份已根據二零二三年股份獎勵計劃的條款及二零二四 年績效目標的達標情況，於二零二五年十一月十三日歸屬於相關的 ...

Group 1 - The stock of Hong Kong-listed company 联邦制药 (03933.HK) experienced a nearly 3% increase in early trading, with a current rise of 2.32% to HKD 12.8 [2] - The trading volume reached HKD 64.0646 million [2]